Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement to integrate MaxQ’s artificial intelligence (AI) software with Samsung NeuroLogica’s medical imaging hardware in the United States and European Union acute care marketplace. As part of this agreement, Samsung NeuroLogica will be able enhance its offerings with MaxQ’s Accipio Ix, part of MaxQ’s Accipio Insight intracranial hemorrhage platform, which supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those patients using adult non-contrast head computed tomography (CT) imaging.

Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago. In 2018, the company is also celebrating its 30th anniversary.

November 26, 2018 — Medical imaging software company Arterys will demonstrate its wide-ranging suite of artificial ...

HeartVista announced its artificial intelligence (AI)-driven, One-Click Autonomous MRI acquisition software for cardiac exams. Integrated with existing magnetic resonance imaging (MRI) scanners, the software uses AI to guide image acquisition.

November 21, 2018 — BTG plc announced the first Ekos CU 4.0 units have been shipped from BTG’s facility in Bothell, Wash ...

Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has been enrolled in a first-of-its-kind study. The study will evaluate the use of Bay Labs’ EchoGPS cardiac ultrasound guidance software to enable certified medical assistants (CMAs) as medical professionals with no prior scanning experience to capture high-quality echocardiograms. The study will also evaluate the use of its EchoMD measurement and interpretation software suite to detect certain types of heart disease among patients 65 years and older undergoing routine physical examinations in primary care settings.

The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for certain FDA-regulated clinical investigations that present no more than minimal risk to human research participants.